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Background
Considerable diversity exists in the immune competency
of cancer patients even within patients of the same diag-
nosis. The relationship between the nature and degree
of immune suppression and the responses to different
targets of immunotherapy will be the key to the rapid
implementation and optimal use of these therapies.
Methods
We have developed a systems based approach to under-
stand immunosuppression in cancer patients by combin-
ing comprehensive whole blood quantitative flow
cytometry and classical bioinformatics analyses. Our
first generation immune profile analysis identified a
unique biomarker consisting of the ratio of CD4+
T cells to CD14+HLA-DRlo/neg monocytes that correlate
with survival rates in over 90 patients with glioblastoma,
non-Hodgkin lymphoma, renal cell carcinoma or ovarian
cancer1. Our second generation technology counts over
150 distinct immune phenotypes including over 25 mye-
loid phenotypes both stimulating and suppressive and
many with no known function2. There are 10 PD-1+ and
CTLA-4+ T cell combinations, dozens of other T cell
phenotypes, as well as cell types rarely included in cancer
immunology including granulocyte phenotypes.
Results
As the analysis is technology and disease agnostic, this
approach is being used across our immune therapy pro-
gram. To date, more than 100 individuals have been
typed. As an example we present preliminary longitudinal
data from newly diagnosed glioblastoma patients enrolled
in a Phase I clinical trial (n=8) receiving a dendritic cell
vaccine with concurrent standard of care demonstrating
immunophenotypic changes during the course of therapy.
Conclusions
The data collected from these studies will provide valuable
insight in the immunological deficits of patients prior to
treatment and phenotypes that contribute to positive or
negative responses. This methodology will likely improve
various aspects of dendritic cell and other cancer immu-
notherapies through the optimization of the targeting of
specific deficits, timing of delivery, and the development of
combinatorial approaches.
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